| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/16/2006 | US20060035908 Thienopyrimidines useful as Aurora kinase inhibitors |
| 02/16/2006 | US20060035907 Methods of treating abnormal cell growth using c-MET and m-TOR inhibitors |
| 02/16/2006 | US20060035906 Converting hydroxyl group in 1-formyl-4-(2-hydroxyethyl) piperazine to a leaving group, reacting with 2-mercaptobenzimidazole , and removing the formyl group; formyl derivative is prepared by formylating 1-(2-hydroxyethyl)piperazine |
| 02/16/2006 | US20060035905 Formulations of phosphodiesterase 5 inhibitors and methods of use |
| 02/16/2006 | US20060035904 Antineoplastic combinations |
| 02/16/2006 | US20060035903 Storage stable perfusion solution for dihydropteridinones |
| 02/16/2006 | US20060035902 crystal structured tetrahydropteridinones, used as polo-like kinase inhibitors for the regulation of eukaryotic cell cycles; antiproliferative agents |
| 02/16/2006 | US20060035901 Methotrexate derivatives useful for treating cancer and arthritis |
| 02/16/2006 | US20060035900 Crystalline forms of ( 6R)-L-erythro-tetrahydrobiopterin dihydrochloride |
| 02/16/2006 | US20060035899 Use of cysteine derivatives for the preparation of a medicament intended to treat pathologies which result from the formation of the heterotrimeric G protein |
| 02/16/2006 | US20060035898 morpholin-4-yl-{3-[3-(1H-pyrazol-4-yl)-1H-pyrazolo[3,4-b]pyridin-5-yl-phenyl}-methanone; FMS-like tyrosine kinase 3 (FLT3), is implicated in cancers, including leukemia, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplasia |
| 02/16/2006 | US20060035897 Trifluoromethyl substituted benzamides as kinase inhibitors |
| 02/16/2006 | US20060035896 Inhibitors of lysophosphatidic acid acyltransferase beta (LPAAT- beta ) activity; cancer screening and therapy |
| 02/16/2006 | US20060035895 Isoxazoline derivatives useful as antimicrobials |
| 02/16/2006 | US20060035894 Phenyl[(2S)-4-(phenylmethyl)morpholin-2-yl]methanol; anxiolytic, antidepressant, cognition activator; rise in the concentration of that neurotransmitter within the synaptic cleft; psycological disorders, attention deficit hyperactivity disorder, obesity; deprotection |
| 02/16/2006 | US20060035893 Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| 02/16/2006 | US20060035892 Nitrosated imidazopyridines |
| 02/16/2006 | US20060035891 (1S, 2R)-N4-(2-Aminocarbonylcyclopent-1-yl)-5-fluoro-N2-[4-(4-methylpiperazin-1-yl)-3-methylphenyl]-2,4-pyrimidinediamine, having antiproliferative activity, used to inhibit cellular proliferation and to treat proliferate diseases such as cancers |
| 02/16/2006 | US20060035890 Compounds and methods for the treatment of ubiquitin conjugating disorders |
| 02/16/2006 | US20060035889 Treatment for methamphetamine addiction and reduction of methamphetamine use using serotonin antagonists |
| 02/16/2006 | US20060035888 Memantine as adjunctive treatment to atypical antipsychotic in schizophrenia patients |
| 02/16/2006 | US20060035887 Process for preparing olanzapine |
| 02/16/2006 | US20060035886 Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
| 02/16/2006 | US20060035885 8-Substituted-6,7,8,9-tetrahydropyrimido [1,2-a] pyrimidin-4-one derivatives |
| 02/16/2006 | US20060035884 N-cyclic sulfonamido inhibitors of gamma secretase |
| 02/16/2006 | US20060035883 Novel serotonin receptor ligands and their uses thereof |
| 02/16/2006 | US20060035882 Condensed benzamide compounds and inhibitors of vanilloid receptor subtype 1 (vr1) activity |
| 02/16/2006 | US20060035881 Use of targeted oxidative therapeutic formulation in endodontic treatment |
| 02/16/2006 | US20060035880 Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
| 02/16/2006 | US20060035879 Organic Compounds |
| 02/16/2006 | US20060035878 Novel use of ansamycin antibiotics and method of screening novel angiogenesis inhibitor |
| 02/16/2006 | US20060035877 administering a phosphodiesterase 4 inhibitor in combination with anti-inflammatory corticosteriod (dexamethasone, fluticasone, beclomethasone, budesonide, flunisolide, mometasone furoate, and triamcinolone acetonide); chronic obstructive pulmonary disease or asthma |
| 02/16/2006 | US20060035876 Combination therapy of an SODm and a corticosteroid for prevention and/or treatment of inflammatory bone or joint disease |
| 02/16/2006 | US20060035875 Remedy for hormone-dependent cancer |
| 02/16/2006 | US20060035874 Pharmaceutical products and composition comprising specific anticholinergic agents, beta-2 agonists and corticosteroids |
| 02/16/2006 | US20060035873 Methods for inducing apolipoprotein e secretion |
| 02/16/2006 | US20060035872 Process for the preparation of 3-oximino steroids |
| 02/16/2006 | US20060035871 Pulverulent phytosterol formulations |
| 02/16/2006 | US20060035870 Carboxylic acid derivatives as IP antagonists |
| 02/16/2006 | US20060035869 Inhibitors of epoxide hydrolases for the treatment of hypertension |
| 02/16/2006 | US20060035868 2' Hydroxy-3'-bromo-3,4,4',5-tetramethoxy-(Z)-stilbene; antimitotic agent; inhibits the assembly of tubulin into microtubules; anticarcinogenic: solid tumor cancers, neovascularization; tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and A-4 (extract from willow tree) |
| 02/16/2006 | US20060035867 For inhibition of bone metastases in prostate cancer patients |
| 02/16/2006 | US20060035866 Mycophenolic Acid having phosphonate groups attached either directly through a covalent bond or through a linking group; improved immunosuppressant activity and pharmacokinetic properties; Intracellular targeting for attaining high concentrations of phosphonate-containing molecules in target cells |
| 02/16/2006 | US20060035865 Lipid-rich plaque regressing agents |
| 02/16/2006 | US20060035864 Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders |
| 02/16/2006 | US20060035863 Noncardiotoxic pharmaceutical compounds |
| 02/16/2006 | US20060035862 Tolerance of 4-(4-(2-pyrrolycarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration |
| 02/16/2006 | US20060035861 Compositions of polyacids and polyethers and methods for their use as dermal fillers |
| 02/16/2006 | US20060035859 Treating severe and acute viral infections |
| 02/16/2006 | US20060035857 Methods and compositions for the diagnosis and treatment of cancer |
| 02/16/2006 | US20060035856 Purified polypeptides having IL-13 receptor activity |
| 02/16/2006 | US20060035855 Purified polypeptides having IL-13 receptor activity |
| 02/16/2006 | US20060035848 Broad-spectrum inhibitor of viruses in the Flaviviridae family |
| 02/16/2006 | US20060035847 e.g. 1,2-Dihydro-4-[(4-isopropoxyphenyl)methyl]-5-methyl-3H-pyrazol-3-one; human SGLT2 (sodium ion / glucose cotransporter 2) inhibitors; antidiabetic and hyperglycemic agents; obesity; synergistic mixture with other active compounds |
| 02/16/2006 | US20060035846 Preventing/correcting functional disorders of the pilosebaceous unit of mammals |
| 02/16/2006 | US20060035845 Use of immune cell specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract |
| 02/16/2006 | US20060035844 Preventive or remedy for diseases caused by hyperglycemia |
| 02/16/2006 | US20060035843 Reacting tanaproget (5-(4,4-dimethyl-2-thioxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile) sodium hydride, and acetobromo- alpha -D-glucuronide acid methyl ester; non-steroidal progesterone receptor agonist; contraceptives; side effect reduction |
| 02/16/2006 | US20060035842 Ophthalmic composition |
| 02/16/2006 | US20060035841 D-xylopyranosyl-phenyl-substituted cycles, medicaments containing such compounds, their use and process for their manufacture |
| 02/16/2006 | US20060035840 Beta-D-Glucopyranosyloxy)-3-(3-fluoro-4-methylbenzyl)-4,6-dimethylpyridine; sodium glucose co-transporter 2 (SGLT2) inhibitors; excellent hypoglycemic effect by excreting excess glucose into the urine through preventing the reabsorption of glucose at the kidney; antidiabetic agents; hyperglycemia |
| 02/16/2006 | US20060035838 Drug therapy for celiac sprue |
| 02/16/2006 | US20060035836 Treatment of acute coronary syndrome with an exendin |
| 02/16/2006 | US20060035833 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035832 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035831 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035830 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060035829 Chemokine combinations to mobilize progenitor/stem cells |
| 02/16/2006 | US20060035828 administering high molecular weight ATIIIs that have been heat treated and/or associated with an oligosaccharide, particularly heparin; treating HAV, HBV, HCV, HIV and corona virus infections and diseases caused by thrombin activation |
| 02/16/2006 | US20060035827 Compositions and methods for the treatment or prevention of gallbladder disease |
| 02/16/2006 | US20060035825 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 02/16/2006 | US20060035810 Regulation of ins(3456)p4 signalling by a reversible kinase phosphatase and methods and compositions related thereto |
| 02/16/2006 | US20060035326 Genes |
| 02/16/2006 | US20060035317 Effect of treatment with 4,5-dihydroxy-2-cyclopenten-1-one (dhcp) on gene expression and quorum-sensing in bacteria |
| 02/16/2006 | US20060035303 JNK3 modulators and methods of use |
| 02/16/2006 | US20060035296 Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes |
| 02/16/2006 | US20060035293 Antibodies, polypeptides and polynucleotides, used for detection, prevention and treatment of diseases caused by gramnegative bacteria |
| 02/16/2006 | US20060035213 POSH nucleic acids, polypeptides and related methods |
| 02/16/2006 | US20060035209 Screening method |
| 02/16/2006 | US20060034957 Vitamin-containing system for stabilising the immune response of animals |
| 02/16/2006 | US20060034954 Medical composition for balancing bodily processes |
| 02/16/2006 | US20060034951 Active fraction having anti-cancer and anti-metastasis isolated from leaves and stems of ginseng |
| 02/16/2006 | US20060034947 Erythritol compositions for nasopharynx cleansing |
| 02/16/2006 | US20060034946 Irrigating solution for neurosurgical procedures |
| 02/16/2006 | US20060034945 Composition for restoring damaged skin |
| 02/16/2006 | US20060034944 Compositions for improving breast health in women |
| 02/16/2006 | US20060034943 Inducing apoptosis in cancer cells; administering cell cycle arresting drug, microtubules and stabilizing agent then exposing to vibrational energy |
| 02/16/2006 | US20060034941 Organ preconditioning, arrest, protection, preservation and recovery |
| 02/16/2006 | US20060034934 Agglomeration of sterol particles |
| 02/16/2006 | US20060034933 Freeze-dried lecithin nanometer powder injection of ursolic acid and its preparation method |
| 02/16/2006 | US20060034932 Anti-angiogenic compositions and methods of use |
| 02/16/2006 | US20060034928 Tablet comprising cetirizine and pseudoephedrine |
| 02/16/2006 | US20060034927 Means of delivering drugs in an ascending zero order release pattern |
| 02/16/2006 | US20060034926 Controlled release system |
| 02/16/2006 | US20060034925 Tumor targeting drug-loaded particles |
| 02/16/2006 | US20060034923 Pharmaceutical compositions for controlled release delivery of biologically active compounds |
| 02/16/2006 | US20060034921 Effervescent bisphosphonate formulation |
| 02/16/2006 | US20060034919 High ibuprofen content granules and their preparation and their use in pharmaceutical dosage forms |
| 02/16/2006 | US20060034918 Buoyant formulations of betaine |
| 02/16/2006 | US20060034917 Coating of tablet cores |